NCT06331195Active, not recruiting
An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)
Effects of an Adapted Brazilian Cardioprotective Diet Supplemented or Not With Phytosterols and/or Krill Oil in Patients With Familial Hypercholesterolemia: the DICA-FH Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
The main objective of this randomized clinical trial is to evaluate the effects of the adapted Brazilian Cardioprotective Diet (DICA Br) supplemented or not with phytosterols and/or krill oil in patients with a probable or definitive diagnosis of familial hypercholesterolemia (FH) according to the the Dutch Lipid Clinic Network (Dutch MEDPED) criteria. In addition, the following will be considered secondary objectives: to perform participants´ whole genome sequencing (WGS); to evaluate the effects of the interventions on lipid profile biomarkers; to evaluate the frequency of mild, moderate and severe adverse events according to study groups; and to evaluate adherence rates according to study groups. In this study, 300 individuals will be randomly enrolled into four groups: 1) DICA Br adapted to the FH context (DICA-FH) + phytosterol placebo + krill oil placebo (control group); 2) DICA-FH + 2g/day of phytosterol + krill oil placebo; 3) DICA-FH + phytosterol placebo + 2g/day of krill oil; and 4) DICA-FH + 2g/day of phytosterol + 2g/day of krill oil. Primary outcomes will be LDL-cholesterol for groups phytosterol vs. placebo and lipoprotein(a) for groups krill oil vs. placebo after 120 days of follow up.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 19 Mar 2024
- Start date
- 23 Oct 2024
- Primary completion date
- 13 Feb 2026
- Lead sponsor
- Hospital do Coracao
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06331195
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 23 Oct 2024 to the primary completion date, 13 Feb 2026
- 24 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- TG ≥ 500mg/dL up to 6 months before screening for the study;
- HIV positive on treatment with detectable viral load or AIDS;
- Chronic use of anti-inflammatories, anticonvulsants and immunosuppressive drugs;
- Use of PCSK9 inhibitors (alirocumab, evolocumab, inclisiran);
Other illness
- Food allergies (foods, dyes, preservatives);
- Chronic inflammatory or autoimmune diseases;
- Known liver disease, chronic kidney disease on dialysis or pancreatitis (acute and chronic);
- Cancer being treated or life expectancy \< 6 months;
- Episode of acute coronary syndrome in the last 60 days;
- Refusal to participate in the study, due to failure to sign the Free and Informed Consent Form.
Age
- Grade III/severe obesity (body mass index \[BMI\] ≥40kg/m² for adults or percentile \>99.9 or z-score \>+3 according to WHO/2006 growth curves for BMI/Age indicator for adolescents);
Other
- Having a "possible" FH result according to the Dutch MEDPED criteria;
- Diagnosis of hypercholesterolemia due to a secondary cause recorded in the medical record;
- Contraindication to the use of phytosterols (for example: diagnosis of sitosterolemia);
- Chemical dependency/alcoholism;
- Pregnancy or lactation;
- Individuals who are unable to perform an anthropometric assessment, at the discretion of the investigator;
- Use of dietary supplements that may interfere with the outcomes of interest (dietary fiber modules, n-3 PUFA, essential fatty acids);
- Participation in other randomized clinical trials;
Who the study is looking for
- Age ≥16 years;
- Definitive (certainty) or probable diagnosis of FH by the Dutch MEDPED criteria;
- Using one of the following treatment regimens for ≥6 weeks according to age:
- \>= 20 years -\> simvastatin 40 mg; lovastatin 40 mg; pravastatin 80 mg; atorvastatin 20 mg; rosuvastatin 10 mg; pitavastatin 4 mg; fluvastatin 80 mg; atorvastatin 40- 80 mg; rosuvastatin 20 - 40 mg; atorvastatin 40 - 80 mg + ezetimibe 10mg; rosuvastatin 20 - 40 mg + ezetimibe 10mg; or simvastatin 40mg + ezetimibe 10mg.
- 16 to 19 years -\> simvastatin 10 - 40 mg; lovastatin 10 - 40 mg; pravastatin 10 - 40 mg; atorvastatin 10 - 40 mg; rosuvastatin 5 - 40 mg; cholestyramine 4 to 16 mg; ezetimibe 10mg (in combination with statin).
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (24)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| OCARA Coordinator of this site? Confirm its status | Belém | Brazil | Unknown status |
| Centro Oncologico de Roraima Coordinator of this site? Confirm its status | Boa Vista | Brazil | Unknown status |
| Instituto de Cardiologia e Transplantes do DF Coordinator of this site? Confirm its status | Brasília | Brazil | Unknown status |
| Universidade do Mato Grosso do Sul Coordinator of this site? Confirm its status | Campo Grande | Brazil | Unknown status |
| Universidade Federal do Mato Grosso Coordinator of this site? Confirm its status | Cuiabá | Brazil | Unknown status |
| Hospital Oto Aldeota Coordinator of this site? Confirm its status | Fortaleza | Brazil | Unknown status |
| Universidade Federal de Goias Coordinator of this site? Confirm its status | Goiânia | Brazil | Unknown status |
| Universidade Federal do Amapá Coordinator of this site? Confirm its status | Macapá | Brazil | Unknown status |
| Centro de Pesquisas Clínicas Dr. Marco Mota Coordinator of this site? Confirm its status | Maceió | Brazil | Unknown status |
| Universidade Federal do Amazonas Coordinator of this site? Confirm its status | Manaus | Brazil | Unknown status |
| Universidade Estadual de Maringá Coordinator of this site? Confirm its status | Maringá | Brazil | Unknown status |
| Santa Casa de Montes Claros Coordinator of this site? Confirm its status | Montes Claros | Brazil | Unknown status |
| Centro de Estudos e Pesquisas em Moléstias Infecciosas Coordinator of this site? Confirm its status | Natal | Brazil | Unknown status |
| Universidade Federal do Tocantins Coordinator of this site? Confirm its status | Palmas | Brazil | Unknown status |
| Universidade Federal do Vale do São Francisco Coordinator of this site? Confirm its status | Petrolina | Brazil | Unknown status |
| Instituto de Pesquisa e Ensino em Saúde Coordinator of this site? Confirm its status | Porto Velho | Brazil | Unknown status |
| Centro de Pesquisa Silvestre Santé Coordinator of this site? Confirm its status | Rio Branco | Brazil | Unknown status |
| Instituto Nacional de Cardiologia Coordinator of this site? Confirm its status | Rio de Janeiro | Brazil | Unknown status |
| Hospital Ana Nery Coordinator of this site? Confirm its status | Salvador | Brazil | Unknown status |
| INCOR Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| Universidade Federal de Sao Paulo Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| Instituto Dante Pazzanese de Cardiologia Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| Hcor Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| Centro de Pesquisa Cardiolima Coordinator of this site? Confirm its status | Teresina | Brazil | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.